404 related articles for article (PubMed ID: 3713372)
1. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
4. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Heymer B; Finger H; Wirsing CH
Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
Phillips NC; Tsao MS
Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
[TBL] [Abstract][Full Text] [Related]
6. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
Ishihara C; Yamamoto K; Hamada N; Azuma I
Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
[TBL] [Abstract][Full Text] [Related]
7. Antigenicity study of muroctasin.
Yamaguchi F; Hattori H; Wagai N; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
[TBL] [Abstract][Full Text] [Related]
8. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
Nagao S; Sato K; Osada Y
Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to Bacteroides gingivalis fimbrial antigen in mice.
Ogawa T; Shimauchi H; Kusumoto Y; Hamada S
Immunology; 1990 Jan; 69(1):8-13. PubMed ID: 1968885
[TBL] [Abstract][Full Text] [Related]
10. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
[TBL] [Abstract][Full Text] [Related]
11. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of the synthetic adjuvant N-acetyl-muramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions.
Souvannavong V; Adam A
Eur J Immunol; 1980 Aug; 10(8):654-6. PubMed ID: 6995138
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of non-specific resistance to infection by muroctasin.
Otani T; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
[TBL] [Abstract][Full Text] [Related]
14. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
15. Induction of colony-stimulating activity in mice by injection of liposomes containing lipophilic muramyl peptide derivatives.
Galelli A; Charlot B; Phillips NC; Chedid L
Cancer Res; 1989 Feb; 49(4):810-5. PubMed ID: 2783556
[TBL] [Abstract][Full Text] [Related]
16. Mutagenicity studies of muroctasin.
Shimada H; Hattori C; Sato T
Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
[TBL] [Abstract][Full Text] [Related]
17. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.
Staruch MJ; Wood DD
J Immunol; 1982 Jan; 128(1):155-60. PubMed ID: 6976368
[TBL] [Abstract][Full Text] [Related]
18. Oral immunoadjuvant activity of lipophilic derivatives of N-acetylglucosaminyl-beta(1-->4)-N-acetylmuramyl-L-alanyl-D-isoglutamin yl-(L)- 2,6-meso-diaminopimeric acid-(D)-amide.
Ogawa T; Shimauchi H; Furuta R; Kawata S; Yokogawa K; Kotani S
Vaccine; 1995 Jul; 13(10):887-9. PubMed ID: 7483759
[TBL] [Abstract][Full Text] [Related]
19. Activation of immune responses by muroctasin.
Akasaki M
Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages.
Endo N
Arzneimittelforschung; 1988 Jul; 38(7A):993-6. PubMed ID: 3190805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]